GlassScriptPhysician profile
Chaturani Ranasinghe
NPI 1144370693
$1,296.48
in general payments reported to CMS, 2019-2025
23 companies · $85.31 in 2025
The $85.31 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $287 · 2021: $121 · 2022: $59.75 · 2023: $281 · 2024: $128 · 2025: $85.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $271.74 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $230.06 | 2019-2024 | Ztlido |
| Boston Scientific Corporation | $159.06 | 2023 | |
| Merck Sharp & Dohme LLC | $83.83 | 2024-2025 | Lynparza, Keytruda |
| Abbott Laboratories | $74.21 | 2019-2020 | |
| Tersera Therapeutics LLC | $56.95 | 2024-2025 | Zoladex |
| Collegium Pharmaceutical, INC. | $47.51 | 2020-2021 | |
| Grt US Holding, INC. | $35.87 | 2022 | |
| Stimwave Technologies Incorporated | $33.71 | 2020 | |
| Daiichi Sankyo INC. | $29.41 | 2024 | Enhertu |
| Si-Bone, INC. | $26.87 | 2023 | |
| Abbvie INC. | $26.78 | 2021-2023 | |
| Allergan, INC. | $25.65 | 2020-2021 | |
| Fidia Pharma USA INC. | $25.30 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $24.05 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $23.87 | 2021 | |
| Stratus Medical, LLC | $22.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.90 | 2020 | |
| Stemline Therapeutics INC. | $18.09 | 2025 | Orserdu |
| Pacira Therapeutics, INC. | $17.51 | 2020 | |
| Averitas Pharma INC. | $14.56 | 2023 | Qutenza |
| Avanos Medical | $14.07 | 2019 | |
| Sentynl Therapeutics, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaturani Ranasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.